cardiovascular-agents and ibopamine

cardiovascular-agents has been researched along with ibopamine* in 3 studies

Reviews

2 review(s) available for cardiovascular-agents and ibopamine

Article	Year
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. International journal of cardiology, 2001, Volume: 80, Issue:1 Large drug trials have become very important to determine which drugs should be used in the treatment of patients with chronic heart failure (CHF). When these trials showed "positive" results, publication of the data soon followed, leading to a substantial impact on prescription patterns. In the case of "negative" results, many times they were not published, or were reported as an abstract or as short paper disclosing only the main findings. In this article we will discuss some of these trials that were conducted in the last 10 years, since we believe they may provide insight into the pathophysiology and treatment options in CHF. Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Pyrazines; Quinolines; Sulfonamides; Xamoterol	2001
[Chronic cardiac insufficiency: current treatment and future outlook]. Revue medicale de la Suisse romande, 1996, Volume: 116, Issue:6 Topics: Adrenergic Antagonists; Aldosterone; Angiotensin II; Cardiotonic Agents; Cardiovascular Agents; Clinical Protocols; Deoxyepinephrine; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Vasoconstrictor Agents	1996

Article

Year

The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.

International journal of cardiology, 2001, Volume: 80, Issue:1

Large drug trials have become very important to determine which drugs should be used in the treatment of patients with chronic heart failure (CHF). When these trials showed "positive" results, publication of the data soon followed, leading to a substantial impact on prescription patterns. In the case of "negative" results, many times they were not published, or were reported as an abstract or as short paper disclosing only the main findings. In this article we will discuss some of these trials that were conducted in the last 10 years, since we believe they may provide insight into the pathophysiology and treatment options in CHF.

Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Pyrazines; Quinolines; Sulfonamides; Xamoterol

2001

[Chronic cardiac insufficiency: current treatment and future outlook].

Revue medicale de la Suisse romande, 1996, Volume: 116, Issue:6

Topics: Adrenergic Antagonists; Aldosterone; Angiotensin II; Cardiotonic Agents; Cardiovascular Agents; Clinical Protocols; Deoxyepinephrine; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Vasoconstrictor Agents

1996

Other Studies

1 other study(ies) available for cardiovascular-agents and ibopamine

Article	Year
Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man. European journal of clinical pharmacology, 1988, Volume: 34, Issue:4 The pharmacokinetics and haemodynamics (phono- and impedance cardiography) of single oral doses of 200 mg ibopamine (SK&F 100168), 400 mg quinidine sulphate, and their combination, have been assessed in 6 healthy male volunteers. No significant differences in the mean pharmacokinetic parameters of either drug were seen between the single and combined doses. Ibopamine caused an increase in mean estimated stroke volume (SV +29% for the maximum change from baseline and +15% cumulatively over the first h) with no change in mean heart rate (HR) or QTc. Quinidine administered concomitantly blunted the response of SV. A tendency to a lower mean concentration of epinine early after administration of the combination may have contributed to the difference. Quinidine alone hardly affected SV (-3% from baseline over the first h), but it did increase mean HR (+6 beats.min-1) and mean QTc (+30 ms). These changes were sustained up to 8 h after dosing, and were not affected by concurrent ibopamine. Topics: Adult; Cardiovascular Agents; Deoxyepinephrine; Dopamine; Drug Interactions; Electrocardiography; Humans; Male; Phonocardiography; Quinidine	1988

Article

Year

Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.

European journal of clinical pharmacology, 1988, Volume: 34, Issue:4

The pharmacokinetics and haemodynamics (phono- and impedance cardiography) of single oral doses of 200 mg ibopamine (SK&F 100168), 400 mg quinidine sulphate, and their combination, have been assessed in 6 healthy male volunteers. No significant differences in the mean pharmacokinetic parameters of either drug were seen between the single and combined doses. Ibopamine caused an increase in mean estimated stroke volume (SV +29% for the maximum change from baseline and +15% cumulatively over the first h) with no change in mean heart rate (HR) or QTc. Quinidine administered concomitantly blunted the response of SV. A tendency to a lower mean concentration of epinine early after administration of the combination may have contributed to the difference. Quinidine alone hardly affected SV (-3% from baseline over the first h), but it did increase mean HR (+6 beats.min-1) and mean QTc (+30 ms). These changes were sustained up to 8 h after dosing, and were not affected by concurrent ibopamine.

Topics: Adult; Cardiovascular Agents; Deoxyepinephrine; Dopamine; Drug Interactions; Electrocardiography; Humans; Male; Phonocardiography; Quinidine

1988